Surrozen, Inc./DE (SRZN) stock
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$28.46−2.21 (-7.21%)
Close on Nov 20, 2026Market cap $334.51MP/E –Yield –
Surrozen free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Surrozen's free cash flow for the twelve months ending Jun 30, 2026 was -$34.98M. For fiscal 2025 it was -$30.37M. The highest annual figure on record is -$17.65M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$30.37M | – |
| FY2024 | Dec 31, 2024 | -$17.65M | – |
| FY2023 | Dec 31, 2023 | -$40.76M | – |
| FY2022 | Dec 31, 2022 | -$44.87M | – |
| FY2021 | Dec 31, 2021 | -$50.08M | – |
| FY2020 | Dec 31, 2020 | -$29.97M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.43M | – |
| Q1 FY2026 | Mar 31, 2026 | -$12.62M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.87M | -269.6% |
| Q3 FY2025 | Sep 30, 2025 | -$9.06M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.13M | – |
| Q1 FY2025 | Mar 31, 2025 | -$9.31M | – |
| Q4 FY2024 | Dec 31, 2024 | $3.46M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$7.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.13M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.49M | – |
| Q4 FY2022 | Dec 31, 2022 | -$353.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.30M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.44M | – |
| Q1 FY2022 | Mar 31, 2022 | -$18.79M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.87M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.94M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.68M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.80M | – |
See a number that looks wrong?